ESTRO 2022 - Abstract Book

S1123

Abstract book

ESTRO 2022

Figure 1

Conclusion This study suggests that radiomic analysis of MR T2-w images can be used to define the optimal concomitant CT regimen for LARC cancer patients. In particular, by providing an indication of the GTV spatial heterogeneity at initial staging, maxFD 3050 seems to be able to predict the probability of 5yDFS. New studies including a larger cohort of patients and external validation sets are recommended to verity the results of this generating-hypotheses study.

PO-1328 Prospective assesment of quality of life before, during and after CRT in patients with anal cancer

F. Fuchs 1 , M. Hoffmann 1 , M. Rottler 1 , G. Goesmann 1 , F. Roeder 2 , S. Gerum 2 , M. Niyazi 1 , C. Belka 1 , F. Walter 1

1 Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; 2 Department of Radiation Oncology, Landeskrankenhaus, Paracelsus Medical University Salzburg, Salzburg, Austria Purpose or Objective Combined chemoradiotherapy (CRT) with fluorouracil (5FU) and mitomycin (MMC) represents standard of care for patients with locally advanced non-metastatic anal cancer and offers good 5 year survival rates up to 90%. In 02/19 we initiated a observational study assessing the treatment tolerability as well as quality of life before, during and after CRT. We present a planned interim analysis. Materials and Methods Patients receiving a CRT (VMAT, 1,8/2,2 to 45/55Gy + 2 cycles of 5FU/MMC) as a defintive therapy for anal cancer at the University hospital LMU, Munich were included in this study. Follow up was performed according to the internal hospital standard. Additionally quality of life before, during and after CRT was systematically assessed using the EORTC questionnaires QLQ-C30, QLQ-CR29, the Wexner-, and LARS score.

Results